Neuroblastoma is cancer that arises in immature nerve cells and affects mostly infants and children.
In a recent study, researchers investigated how natural killer cells target breast cancer using the body's own immune system.
Researchers from the Wellcome Sanger Institute and the University of Cambridge discovered that in children with neuroblastoma—a tumor of immature nerve cells—platinum chemotherapy created mutations in the genome that might lead to leukemia in some children later on.
A pre-clinical study for melanoma and neuroblastoma shows that a customized tumor cell vaccine technique that targets Myc oncogenes coupled with checkpoint therapy produces an active immune response that bypasses antigen selection and immune privilege.
Biologically active compounds from the marine fungus Penicillium dimorphosporum protect cells from paraquat, the highly toxic herbicide with no remedy, and might enhance the action of some drugs.
In the field of structural biology, certain molecules are so uncommon that they can only be captured with a special set of tools.
With two commercially available inhibitors, the cell cycle of the cancer cells in the childhood tumor neuroblastoma can be disrupted at a key point causing tumor cell death.
CAR T therapy has transformed the treatment for leukemia. Regrettably, the therapy is not effective enough to treat solid tumors, like neuroblastoma.
A phase 1 trial involving 12 children with relapsed neuroblastoma - a hard-to-treat pediatric cancer - shows that anticancer CAR T cells displayed signs of efficacy against these tumors while avoiding damage to nerve tissue.
Last year, researchers at the University of California, Riverside, identified the early origins of neural crest cells -- embryonic cells in vertebrates that travel throughout the body and generate many cell types -- in chick embryos.
Natural killer T (NKT) cells, a type of immune cells known for their potent anti-cancer properties in murine tumor models, have been developed into a novel form of immunotherapy to treat patients with cancer.
A treatment that uses immune system T cells, combined with an immune-boosting drug packaged in an injectable gel, was found to preserve the vision of mice implanted with tissue from a human eye cancer known as retinoblastoma.
A drug has shown great promise in the treatment of neuroblastoma, an aggressive form of childhood cancer. The study was led by researchers at Lund University in Sweden, and is published in the journal Science Translational Medicine.
Neuroblastoma, is often diagnosed during childhood. It is responsible for causing 15% of all malignancy death in childhood.
Australian researchers have discovered that removing copper from the blood can destroy some of the deadliest cancers that are resistant to immunotherapy using models of the disease.
An MRI scan used for heart disease could help assess whether children's cancers are especially aggressive and spot early signs that treatments are working.